Patents Assigned to Universite Montpellier 2 Sciences et Techniques
-
Patent number: 10702860Abstract: The use, after heat treatment, of manganese accumulating plants for carrying out chemical reactions.Type: GrantFiled: July 23, 2013Date of Patent: July 7, 2020Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUESInventors: Claude Grison, Vincent Escande
-
Patent number: 10463901Abstract: A method of implementing organic synthesis reactions uses a composition containing a metal catalyst originating from a calcined plant. The plants can be from the Brassicaceae, Sapotaceae and Convolvulaceae family, and the metal catalyst contains metal in the M(II) form such as zinc, nickel, manganese, lead, cadmium, calcium, magnesium or copper. Examples of the organic synthesis reactions include halogenations, electrophilic reactions, cycloadditions, transesterification reactions and coupling reactions, among others.Type: GrantFiled: July 27, 2017Date of Patent: November 5, 2019Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUESInventors: Claude Grison, Jose Escarre
-
Patent number: 10066029Abstract: A composition derived from the acid treatment of ashes obtained after heat treatment of selected plants or plant material is provided. The selected plants accumulate metal from the platinum group (platinoids). The compositions can be used to produce catalysts for performing various organic synthesis reactions.Type: GrantFiled: July 15, 2014Date of Patent: September 4, 2018Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S), UNIVERSITE MONTPELLIER 2, SCIENCES ET TECHNIQUESInventors: Claude Grison, Vincent Escande, Clemence Bes, Brice-Loic Renard
-
Patent number: 9896461Abstract: The invention concerns a mono- or polyfunctional polysilylated organosilane compound, and the method for preparing same.Type: GrantFiled: July 8, 2013Date of Patent: February 20, 2018Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S), ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER, UNIVERSITE MONTPELLIER, 2 SCIENCES ET TECHNIQUESInventors: Michel Wong Chi Man, Xavier Cattoën, Kristyna Bürglova, Jana Hodacova
-
Patent number: 9814758Abstract: The invention relates to fragments of the Death-Domain Associated protein (DAXX protein) and of the Fas-Associated Death Domain protein (FADD protein) that inhibit cell apoptosis, in particular cell apoptosis mediated by the Fas receptor. The invention also relates to derivatives of said anti-apoptotic fragments, conjugates comprising said fragments, pharmaceutical compositions comprising said fragments, and to the medical applications of said fragments, derivatives, conjugates, and pharmaceutical compositions thereof in the treatment or prevention of diseases and conditions associated with apoptosis.Type: GrantFiled: November 17, 2011Date of Patent: November 14, 2017Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS, UNIVERSITE MONTPELLIER 2-SCIENCES ET TECHNIQUE, UNIVERSITE DE MONTPELLIER 1Inventors: Stéphanie Barrere, Joël Nargeot, Bernard Lebleu, Prisca Boisguerin, Christophe Piot
-
Patent number: 9744391Abstract: A method of implementing organic synthesis reactions uses a composition containing a metal catalyst originating from a calcined plant. The plants can be from the Brassicaceae, Sapotaceae and Convolvulaceae family, and the metal catalyst contains metal in the M(II) form such as zinc, nickel, manganese, lead, cadmium, calcium, magnesium or copper. Examples of the organic synthesis reactions include halogenations, electrophilic reactions, cycloadditions, transesterification reactions and coupling reactions, among others.Type: GrantFiled: August 21, 2015Date of Patent: August 29, 2017Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUESInventors: Claude Grison, Jose Escarre
-
Patent number: 9694074Abstract: Disclosed are nanovectors of formula (I) that can be used simultaneously for the targeting, imaging and treatment, by photodynamic therapy, of cancer cells, and to biodegradable silicon nanoparticles containing a variety of photosensitizing molecules, in particular porphyrins, capable of targeting diseased cells and inducing cell death by excitation in the near-infrared region (>600 nm) in monophotonic and biphotonic modes. In formula (I), (AA) is a porous silicon nanoparticle.Type: GrantFiled: March 26, 2013Date of Patent: July 4, 2017Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIERInventors: Frederique Cunin, Jean-Olivier Durand, Michael J. Sailor, Marcel Garcia, Emilie Secret, Magali Gary-Bobo, Marie Maynadier, Alain Morere
-
Patent number: 9689786Abstract: A method for determining the size distribution of a mixture of molecule or particle species including the steps of: injecting a sample of the mixture to be analyzed inside a capillary in which an eluent is flowing; transporting the sample injected along the capillary from an injection section to a detection section thereof, in experimental conditions suitable to generate a Taylor dispersion phenomenon that is measurable at the level of the detection section; generating, by a suitable sensor included in the detection section, a signal characteristic of the Taylor dispersion of the transported sample; processing the detection signal in order to obtain an experimental Taylor signal S(t); and analyzing the experimental Taylor signal ?(t), wherein the step of analyzing an experimental Taylor signal ?(t) of a sample of the mixture consists of searching an amplitude distribution P(G(c)) that allows the experimental Taylor signal ?(t)? to be broken down into a sum of Gaussian functions.Type: GrantFiled: June 26, 2013Date of Patent: June 27, 2017Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), UNIVERSITE MONTPELLIER 1, UNIVERSITE MONTPELLIER 2, SCIENCES ET TECHNIQUESInventors: Hervé Cottet, Luca Cipelletti, Michel Martin, Jean-Philippe Biron
-
Patent number: 9656947Abstract: The present invention concerns a process for preparing a compound of formula (I) by reaction between a compound of formula (II) and a compound of formula (III) in the presence of a copper-containing catalyst, a ligand and base. The invention also concerns the implementing of this process for the preparation of building blocks to prepare molecules of interest in particular in the pharmaceutical, agro-chemical fields, etc.Type: GrantFiled: June 6, 2013Date of Patent: May 23, 2017Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S), UNIVERSITE MONTPELLIER 2, SCIENCES ET TECHNIQUES, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIERInventors: Marc Taillefer, Florian Monnier, Anis Tlili, Grégory Danoun
-
Patent number: 9546371Abstract: The present invention concerns a chimeric polypeptide comprising several polypeptide domains, which is capable of being secreted in association with membrane vesicles and in particular exosomes. The present invention also concerns a polypeptide constituted by one of said domains for the secretion of a peptide or polypeptide of interest in association with membrane vesicles and in particular exosomes. The invention also concerns the use of polypeptides of the invention and of polynucleotides coding for said polypeptides for the production of immunogenic compositions based on exosomes or based on DNA or for screening protein interactions.Type: GrantFiled: March 18, 2009Date of Patent: January 17, 2017Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE MONTPELLIER 2 SCIENCE ET TECHNIQUESInventors: Robert Zaine El Abiddine Mamoun, Bernadette Nadine Trentin, Michel Vidal
-
Publication number: 20160289650Abstract: The present invention relates to compounds comprising a polypeptide comprising an amino acid sequence derived from the sequence of a cyclin-dependent kinase (CDK) and at least one fluorophore coupled to an amino acid of said polypeptide. The invention also relates to said compounds associated with a technology enabling their intracellular delivery. The present invention also relates to the use of such compounds, or of compositions comprising said compounds, for determining if a product is capable of modulating the conformation of a CDK. More particularly, a compound according to the invention is usable for high-content high-throughput screening.Type: ApplicationFiled: November 13, 2013Publication date: October 6, 2016Applicants: Centre National de la Recherche Scientifique (CNRS), Universite Montpellier 2 Sciences et TechniquesInventors: May Catherine Morris, Gilles Divita, Morgan Pellerano
-
Patent number: 9309275Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3?-deoxy nucleoside compounds according to Formula 3001a or 3001b: or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Base1 and Base2 are as provided herein.Type: GrantFiled: March 3, 2014Date of Patent: April 12, 2016Assignees: IDENIX PHARMACEUTICALS LLC, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ MONTPELLIER 2 SCIENCES ET TECHNIQUESInventors: Alistair James Stewart, Adel M. Moussa, Benjamin Alexander Mayes, Francois-Rene Alexandre, Dominique Surleraux, Christophe Claude Parsy, Claire Pierra, David Dukhan, Gilles Gosselin
-
Patent number: 9296778Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: GrantFiled: May 21, 2013Date of Patent: March 29, 2016Assignees: Idenix Pharmaceuticals, Inc., Centre National De La Recherche Scientifique, Universite Montpellier 2 Sciences Et TechniquesInventors: Christophe Claude Parsy, Francois-Rene Alexandre, Cyril B. Dousson, David Dukhan, Gilles Gosselin, Houcine Rahali, Dominique Surleraux
-
Patent number: 9274110Abstract: The present invention relates to a method for the in vitro diagnosis of active tuberculosis, comprising a step of contacting lymphocytes of a patient suspected to have active tuberculosis with at least one protein of mycobacteria, said protein being an enzyme having a lipolytic activity, and a step of detecting the presence of specific activated lymphocytes.Type: GrantFiled: June 1, 2012Date of Patent: March 1, 2016Assignees: Universite Montpellier 2 Sciences et Technique, Universite Montpellier 1, Centre Hospitalier Universitaire de Montpellier, Centre National de La Recherche ScientifiqueInventors: Edouard Tuaillon, Pierre-Alain Rubbo, Stephane Canaan, Laurent Kremer, Nicolas Nagot, Philippe Van De Perre, Jean-Pierre Vendrell
-
Patent number: 9233931Abstract: The present invention relates to a compound of one of the formulas I to XXI; a pharmaceutical composition comprising at least one such compound; and the use of at least one such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.Type: GrantFiled: November 4, 2013Date of Patent: January 12, 2016Assignees: CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUESInventors: Jamal Tazi, David Grierson, Florence Mahuteau-Betzer, Pierre Roux
-
Patent number: 9211300Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are according to Formula 1501: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, PD, RA, RB, RC, L, M and Z are as described herein.Type: GrantFiled: December 17, 2013Date of Patent: December 15, 2015Assignees: Idenix Pharmaceuticals LLC, Centre National De La Recherche Scientifique, Universite Montpellier 2 Sciences et TechniquesInventors: Benjamin Alexander Mayes, Adel M. Moussa, Alistair James Stewart, Gilles Gosselin
-
Publication number: 20150344552Abstract: Disclosed are specific antibodies against the protein Trio, their method of production, and their use in in vitro cancer prognostic method. Also described are the antigens enabling production of the antibodies.Type: ApplicationFiled: December 6, 2013Publication date: December 3, 2015Applicants: UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Anne DEBANT, Jerome BOUDEAU
-
Patent number: 9184459Abstract: The invention relates to a polymer comprising at least one polymeric chain of a first type, the said chain comprising at least two blocks, the same or different, the said blocks comprising repeat units derived from the polymerisation of styrene monomers, the said units comprising at least one phenyl pendant group carrying at least one —SO3R group, R possibly being a hydrogen atom, an alkyl group or cationic counter-ion, the said two blocks being separated by a spacer group, the spacer group is a perfluorocarbon group.Type: GrantFiled: September 21, 2011Date of Patent: November 10, 2015Assignees: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE MONTPELLIER 2, SCIENCES ET TECHNIQUES, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIERInventors: Pierrick Buvat, Jannick Bigarre, Renaud Perrin, Bruno Ameduri, Aurelien Soules, Bernard Boutevin
-
Patent number: 9184585Abstract: The invention relates to a static converter connected between an electrical voltage source and an electrical load, said converter including a main static conversion arm comprising an output electronic switching cell and a backup conversion arm having identical structures. The static converter includes a pair of fuses connected on either side of the main arm, and a switching circuit comprising a connection element connecting the backup arm to the connection points between the fuses and the input terminals of the main arm, such that, when a fault occurs on one of the switching cells forming the main arm, a stable conductive link is established between the two fuses, the main arm is isolated by the two fuses, and the backup arm is spontaneously connected to the output of the main arm via the conductive line and replaces the main arm.Type: GrantFiled: June 24, 2011Date of Patent: November 10, 2015Assignees: Institut National Polytechnique de Toulouse, Universite de Toulouse II Le Mirail, Universite Montpellier 2, Sciences et Techniques, Centre National de la Recherche Scientifique (C.N.R.S.)Inventors: Jean-Jacques Huselstein, Emmanuel Sarraute, Frédéric Richardeau, Thierry Martire
-
Patent number: 9175334Abstract: The invention relates to an in vitro method for identifying microRNAs or the target mRNAs thereof, the expression of which during the infection of cells by a virus using a cell receptor and at least one cell co-receptor for entering the cell, is specifically modified on the basis of the cell co-receptor used by the virus for its entering the cells, comprising: i) determining the microRNA expression levels in a test cell expressing a receptor, a first co-receptor and at least one other co-receptor, after infection by a first virus using the first co-receptor and by at least one other virus using another co-receptor, respectively; ii) identifying the microRNAs, the expression level of which is modulated during the infection by each of the viruses in relation to the expression level in the uninfected cells; iii) comparing the thus-identified microRNAs; iv) selecting the microRNAs, the modification of the expression level of which is specific to the use of a co-receptor; v) optionally identifying the target mRType: GrantFiled: September 1, 2010Date of Patent: November 3, 2015Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES, UNIVERSITE PARIS-DIDEROT-PARIS 7Inventors: Charles-Henri Lecellier, Valerie Courgnaud, Manuella Bouttier, Diane Descamps, Gilles Collin